Compare Recursion Pharmaceuticals Inc (RXRX) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Taskus Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3× Taskus Inc's market cap, and Taskus Inc is more actively traded (201,303 versus 30,789,535). Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Taskus Inc for 34 Days on average.
| RXRX | TASK | |
|---|---|---|
Market Cap | $2.14B | $723.41M |
Volume | 30,789,535 | 201,303 |
Sector | Health | Technology |
52-Week High | $6.79 | $14.69 |
52-Week Low | $2.84 | $4.57 |
Typical Hold Time | 22 Days | 34 Days |
Enterprise Value | $1.66B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
TaskUs trades at $7.89, down 0.88% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin of 8.75%. Valuation metrics appear attractive with P/E of 6.8 and P/S of 0.6. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected. Analyst consensus is bullish with 55% buy ratings and $9.33 price target, representing 18% upside potential.
The stock presents value opportunity with solid profitability and AI services growth offsetting Trust & Safety declines. Key risks include labor cost pressures and client concentration. Positive cash flow generation and institutional accumulation support the bullish case, though technical weakness suggests near-term consolidation may continue before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
